top of page
News, Events and Updates
Search
Jun 12, 2023
Anavex Life Sciences Reports Publication in Medical Journal for Continued Commitment to Improve RSBQ
Jun 6, 2023
Completion of ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Jun 1, 2023
ANAVEX Announces New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73 (blarcamesine)
May 9, 2023
Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results
May 2, 2023
Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Resultson Tuesday May 9, 2023
May 1, 2023
Anavex Life Sciences Announces Issuance of New U.S. Patent ANAVEX®2-73 (blarcamesine)
Apr 25, 2023
Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Apr 10, 2023
Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023
Mar 30, 2023
ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48Week Phase 2 Extension Study in PDD
Mar 9, 2023
Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as VP Head of Biostatistics
Feb 7, 2023
Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results
4
5
6
7
8
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
